# First-line CBDCA/PTX/LEN/Pembrolizumab Combination for Previously Untreated Advanced or Recurrent Thymic Carcinomas (Artemis)

> **NCT05832827** · PHASE2 · RECRUITING · sponsor: **National Cancer Center, Japan** · enrollment: 35 (estimated)

## Conditions studied

- Untreated Advanced or Recurrent Thymic Carcinomas

## Interventions

- **DRUG:** MK-3475
- **DRUG:** Lenvatinib
- **DRUG:** Carboplatin
- **DRUG:** Paclitaxel

## Key facts

- **NCT ID:** NCT05832827
- **Lead sponsor:** National Cancer Center, Japan
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-09-04
- **Primary completion:** 2025-12-31
- **Final completion:** 2028-06-30
- **Target enrollment:** 35 (ESTIMATED)
- **Last updated:** 2023-10-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05832827

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05832827, "First-line CBDCA/PTX/LEN/Pembrolizumab Combination for Previously Untreated Advanced or Recurrent Thymic Carcinomas (Artemis)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05832827. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*